About Arctoris

Our mission is clear: with millions dying of diseases like cancer, heart disease and diabetes every year, the world continues to be in desperate need of novel and better therapies to extend and improve lives. However, bringing a new drug to market is both slow and expensive, requiring billions of dollars and decades of R&D for even a single new drug to enter the clinic.

How does Arctoris transform drug discovery? 

At Arctoris, we have developed the world’s first fully automated drug discovery platform to meet these challenges. Not only does embracing total automation expedite project timelines and increase efficiency, it also allows you to generate deeper, higher quality data to better answer your research questions and make more informed decisions. Ultimately, it means bringing better treatments to those that need them, faster. 

Our team

Martin-Immanuel Bittner Co-Founder & CEO

Martin completed his medical degree in Germany and his DPhil in Oncology as a Rhodes Scholar at the University of Oxford. He worked in both clinical trials and drug discovery, is actively involved in several European cancer research organisations, and in 2018 was elected a member of the Young Academy of the German National Academy of Sciences in recognition of his research achievements.

Thomas A. Fleming Co-Founder & COO

Tom is a Royal Academy of Engineering SME Leader, and was formerly a cancer researcher and Fellow of the Royal Commission of 1851 at the University of Oxford. A chemist by background, he worked both at leading CROs and pharmaceutical corporations. Tom has unique insights into drug discovery, including the critical steps from target identification & validation to high-throughput screening & lead optimisation.

Kilian R. Dinkelaker Co-Founder & CFO

Kilian is a former management consultant and econometrics researcher. His track record entails 10 years of industry experience with a focus on technology-driven business creation and corporate finance primarily in the European and Asia-Pacific markets. He graduated from WHU - Otto Beisheim School of Management.

Professor John Mattick Board member

Professor Mattick AO FAA FTSE FAHMS FRSN HonFRCPA GAICD is a renowned molecular biologist and life sciences executive. He was the Foundation Director of the Australian Genome Research Facility, Executive Director of the Garvan Institute of Medical Research and CEO of Genomics England. Professor Mattick has received numerous honours and awards and adds his unique insights and expertise to the board of Arctoris.

Patrick Pichette Board advisor

Patrick is a general partner at leading Canadian venture capital firm Inovia Capital, heading their London office. He is also a board member of Twitter and the Trudeau Foundation, and an active angel investor. Previously, he was Senior Vice President and CFO of Google, CFO of Bell Canada, and partner at McKinsey. He advises the board of Arctoris on its growth and financial strategy.

Our Investors

and a group of exceptional angels and entrepreneurs

Join our team

Would you like to join an exciting and fast-growing team that strives to transform drug discovery and bring better treatments to patients sooner? If so, then get in touch today.